Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery

Arredondo, Jorge; Baixauli, Jorge; Pastor, Carlos; Chopitea, Á.; Sola, J. J.; González, I.; Cienfuegos, Javier A.; Martínez, P.; Rodríguez, Javier Jacob; Hernández-Lizoain, José Luís

doi:10.1007/s12094-016-1539-4

Cited by 72 publications

(67 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although neoadjuvant chemotherapy is not routinely administered in locally advanced colorectal cancer patients, several authors have demonstrated benefits with a neoadjuvant chemotherapy-alone approach [25,26]. Studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers [25,26].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer

et al. 2020

View full text Add to dashboard Cite

Background: This study aimed to evaluate the safety and feasibility of self-expanding metallic stent (SEMS) followed by neoadjuvant chemotherapy prior to elective surgery for obstructing left-sided colon cancer. Methods: Eleven consecutive patients with obstructing left-sided colon cancer between May 2014 and November 2015 were included retrospectively. All patients received SEMS followed by neoadjuvant chemotherapy. The primary outcome measure was stoma and laparoscopic surgery. Results: Chemotherapy was with two cycles of CAPOX (54.5%) or three cycles mFOLFOX6 (45.5%). Median serum albumin and hemoglobin levels before surgery were significantly higher than before neoadjuvant chemotherapy (p = 0.01 and p = 0.008 respectively) and before SEMS (p = 0.01 and p = 0.003 respectively). Median bowel wall thickness proximal to the upper edge of tumor was significantly more before neoadjuvant chemotherapy than before stent (p = 0.003), and significantly less before surgery than before neoadjuvant chemotherapy (p = 0.003). No patient underwent stoma creation. Laparoscopic surgery was performed in nine (81.8%) patients. No local recurrence or metastases developed over median cancer-specific follow-up of 44 months (range, 37-55 months). Conclusion: SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer.

show abstract

“…Although neoadjuvant chemotherapy is not routinely administered in locally advanced colorectal cancer patients, several authors have demonstrated benefits with a neoadjuvant chemotherapy-alone approach [25,26]. Studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers [25,26].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although neoadjuvant chemotherapy is not routinely administered in locally advanced colorectal cancer patients, several authors have demonstrated benefits with a neoadjuvant chemotherapy-alone approach. 25,26 Studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers. 25,26 All patients in our study completed neoadjuvant chemotherapy without experiencing any major toxicities.…”

Section: Discussionmentioning

confidence: 99%

“…25,26 Studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers. 25,26 All patients in our study completed neoadjuvant chemotherapy without experiencing any major toxicities. Although no patient achieved complete pathologic response in our study, tumor reduction was achieved in all patients.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer

Han

Wang

Zeng

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: This study aimed to evaluate the safety and feasibility of self-expanding metallic stent (SEMS) followed by neoadjuvant chemotherapy prior to elective surgery for obstructing left-sided colon cancer. METHODS: Eleven consecutive patients with obstructing left-sided colon cancer between May 2014 and November 2015 were included retrospectively. All patients received SEMS followed by neoadjuvant chemotherapy. The primary outcome measure was stoma and laparoscopic surgery. RESULTS: Chemotherapy was with two cycles of CAPOX (54.5%) or three cycles mFOLFOX6 (45.5%). Median serum albumin and hemoglobin levels before surgery were significantly higher than before neoadjuvant chemotherapy (p = 0.01 and p = 0.008 respectively) and before SEMS (p = 0.01 and p = 0.003 respectively). Median bowel wall thickness proximal to the upper edge of tumor was significantly more before neoadjuvant chemotherapy than before stent (p = 0.003), and significantly less before surgery than before neoadjuvant chemotherapy (p = 0.003). No patient underwent stoma creation. Laparoscopic surgery was performed in nine (81.8%) patients. No local recurrence or metastases developed over median cancer-specific follow-up of 44 months (range, 37-55 months). CONCLUSION: SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer.

show abstract

“…Although neoadjuvant chemotherapy is not routinely administered in locally advanced colorectal cancer patients, several authors have demonstrated benefits with a neoadjuvant chemotherapy-alone approach. 20,[25][26][27] A single-center phase II study conducted at Memorial Sloan-Kettering Cancer Center evaluated neoadjuvant chemotherapy with six cycles of FOLFOX plus bevacizumab in locally advanced rectal cancer patients and showed that neoadjuvant chemotherapy was relatively safe and capable of inducing major tumor regression. 25 Four cycles of neoadjuvant mFOLFOX6 chemotherapyalone approach has also shown promising efficacy for locally advanced rectal cancer in the FOWARC study.…”

Section: Discussionmentioning

confidence: 99%

“…26 Other studies have shown that neoadjuvant chemotherapy with CAPOX or FOLFOX is effective and safe in patients with locally advanced colon cancers. 20,27 All patients in our study completed neoadjuvant chemotherapy without experiencing any major toxicities. Although no patient achieved complete pathologic response in our study, tumor reduction was achieved in all patients.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer

Han

Wang

Zeng

et al. 2019

Preprint

View full text Add to dashboard Cite

BACKGROUND: Stoma is reported to be frequent in self-expanding metallic stent (SEMS) treated patients with obstructing left-sided colon cancer than in those with non-obstructing surgery. This study aimed to evaluate the safety and feasibility of SEMS followed by neoadjuvant chemotherapy prior to elective surgery for obstructing left-sided colon cancer. METHODS: Eleven consecutive patients with obstructing left-sided colon cancer between May 2014 and November 2015 were included retrospectively. All patients received SEMS followed by neoadjuvant chemotherapy. The primary outcome measure was stoma and laparoscopic surgery. RESULTS: Chemotherapy was with two cycles of CAPOX (54.5%) or three cycles mFOLFOX6 (45.5%). Median serum albumin and hemoglobin levels before surgery were significantly higher than before neoadjuvant chemotherapy (p = 0.01 and p = 0.008 respectively) and before SEMS (p = 0.01 and p = 0.003 respectively). Median bowel wall thickness proximal to the upper edge of tumor was significantly more before neoadjuvant chemotherapy than before stent (p = 0.003), and significantly less before surgery than before neoadjuvant chemotherapy (p = 0.003). No patient underwent stoma creation. Laparoscopic surgery was performed in nine (81.8%) patients. No local recurrence or metastases developed over median cancer-specific follow-up of 44 months (range, 37-55 months). CONCLUSION: SEMS followed by neoadjuvant chemotherapy prior to elective surgery appears to be safe and well tolerated in patients with obstructing left-sided colon cancer.NCT02972541; retrospectively registered

show abstract

Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery

Abstract: Preoperative chemotherapy in LACC patients is safe and able to induce major tumor regression. Survival times are encouraging, and further research seems warranted.

Cited by 72 publications

References 25 publications

Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer

Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer

Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer

Efficacy and safety of self-expanding metallic stent placement followed by neoadjuvant chemotherapy and scheduled surgery for treatment of obstructing left-sided colonic cancer

Contact Info

Product

Resources

About